Vimarsana
Biggest News Aggregation in the World

Page 17 - Safety Risks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Risks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Risks Today - Breaking & Trending Today

China's top procuratorate supervises probe into deadly coal mine fire - Vimarsana News

China's top procuratorate supervises probe into deadly coal mine fire

China Supreme People Procuratorate (SPP) will supervise the investigation into a fire at a coal mine office building in north China Shanxi Province, a.....

In Vitro Toxicology Testing Market worth $17.1 billion by 2028 | strategic planning, business opportunity - Vimarsana News

In Vitro Toxicology Testing Market worth $17.1 billion by 2028 | strategic planning, business opportunity

The global in vitro toxicology testing market in terms of revenue was estimated to be worth $10.8 billion in 2023 and is poised to reach $17.1 billion by 2028, growing at a CAGR of 9.5% from 2023 to 2028.

President Biden Takes Bold Action with Landmark Executive Order on AI Regulation - Vimarsana News

President Biden Takes Bold Action with Landmark Executive Order on AI Regulation

By Stacy M. Brown, NNPA Newswire Senior National Correspondent @StacyBrownMedia President Joe Biden has issued a sweeping executive order to safeguard against potential threats posed by artificial intelligence (AI). The order, announced on Monday, seeks to prevent the misuse of AI technology for developing destructive weapons or launching highly potent cyberattacks. The move marks a

10 Things You Should Never Buy Used - Vimarsana News

10 Things You Should Never Buy Used

No matter how good garage or estate-sale deals look, bargain hunters say don’t buy 10 kinds of used merchandise for health and safety reasons.

Source: aarp.org
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study - Vimarsana News

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

If the therapy is approved, Vertex has proposed a 15-year follow up of patients to evaluate the safety outcomes of the therapy. A vaso-occlusive crisis occurs when sickled red blood cells block blood flow to the point that tissues become deprived of oxygen and causes pain. The panel members said the 15-year follow up will help generate data from real-time monitoring of the therapy, which uses the new gene editing CRISPR technology.

Source: yahoo.com